Agilent Introduces Three New Microarrays for Prenatal and Postnatal Research
March 03 2020 - 7:00AM
Business Wire
Delivering up-to-date content for cytogenetic testing needs
Agilent Technologies Inc. (NYSE: A) today introduced three new
microarrays to meet the needs of cytogenetic laboratories
conducting both prenatal and postnatal research.
The new Agilent GenetiSure Cyto microarrays include updated,
clinically relevant content from respected databases. The probes on
the Cyto microarrays provide high-resolution detection of copy
number variations, and copy-neutral loss of heterozygosity
associated with developmental delay, neuropsychiatric disorders,
intellectual disability, congenital anomalies, or unexplained
dysmorphic features in constitutional DNA samples.
“With the progression of next-generation sequencing, new
gene-disease associations are being uncovered, and databases are
evolving rapidly to include these discoveries,” said Kevin Meldrum,
general manager of Agilent’s Genomics Solution Division. “Clinical
researchers need to have a platform that will allow them to test
for these relevant genetic aberrations.”
Meldrum noted that Agilent’s new arrays focus on clinically
relevant regions with different specifications, depending on
application (prenatal and postnatal research) down to exon-level
resolution.
Dr. Svetlana Yatsenko, who directs the cytogenetics laboratory
at the University of Pittsburgh Medical Center’s Magee-Women’s
Hospital, in Pittsburgh, Pennsylvania, had this to say about the
new microarrays:
“As a high-volume molecular cytogenetics laboratory, one of our
key needs is having a microarray platform that contains the latest
clinically-relevant content. Agilent GenetiSure Cyto microarrays
meet this need. With a targeted design covering over 3600 genes and
compatibility with a wide range of clinically relevant samples, we
see it as a compelling solution for any laboratory trying to
implement or upgrade their microarray testing needs.”
Agilent is a leading manufacturer of high-quality microarrays
for copy number analysis and provides a complete workflow from
sample preparation to interpretation.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To
receive the latest Agilent news, subscribe to the Agilent
Newsroom. Follow Agilent on
LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200303005336/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2024 to May 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From May 2023 to May 2024